Literature DB >> 27099087

Central Nervous System Oxygen Toxicity and Hyperbaric Oxygen Seizures.

Edward P Manning.   

Abstract

INTRODUCTION: The use of hyperbaric oxygen (O2) as a therapeutic agent carries with it the risk of central nervous system (CNS) O2 toxicity.
METHODS: To further the understanding of this risk and the nature of its molecular mechanism, a review was conducted on the literature from various fields.
RESULTS: Numerous physiological changes are produced by increased partial pressures of oxygen (Po2), which may ultimately result in CNS O2 toxicity. The human body has several equilibrated safeguards that minimize effects of reactive species on neural networks, believed to play a primary role in CNS O2 toxicity. Increased partial pressure of oxygen (Po2) appears to saturate protective enzymes and unfavorably shift protective reactions in the direction of neural network overstimulation. Certain regions of the CNS appear more susceptible than others to these effects. Failure to decrease the elevated Po2 can result in a tonic-clonic seizure and death. Randomized, controlled studies in human populations would require a multicenter trial over a long period of time with numerous endpoints used to identify O2 toxicity.
CONCLUSIONS: The mounting scientific evidence and apparent increase in the number of hyperbaric O2 treatments demonstrate a need for further study in the near future.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27099087     DOI: 10.3357/AMHP.4463.2016

Source DB:  PubMed          Journal:  Aerosp Med Hum Perform        ISSN: 2375-6314            Impact factor:   1.053


  16 in total

1.  Audit of practice in Australasian hyperbaric units on the incidence of central nervous system oxygen toxicity.

Authors:  Susannah Sherlock; Mandy Way; Alexis Tabah
Journal:  Diving Hyperb Med       Date:  2018-06-30       Impact factor: 0.887

2.  Decompressing recompression chamber attendants during Australian submarine rescue operations.

Authors:  Michael P Reid; Andrew Fock; David J Doolette
Journal:  Diving Hyperb Med       Date:  2017-09       Impact factor: 0.887

Review 3.  Diving and attention deficit hyperactivity disorder.

Authors:  Abraham L Querido; Robert A van Hulst
Journal:  Diving Hyperb Med       Date:  2019-03-31       Impact factor: 0.887

4.  Decompressing rescue personnel during Australian submarine rescue operations.

Authors:  Michael P Reid; Andrew Fock; David J Doolette
Journal:  Diving Hyperb Med       Date:  2017-09       Impact factor: 0.887

5.  Inert gas narcosis in scuba diving, different gases different reactions.

Authors:  Monica Rocco; P Pelaia; P Di Benedetto; G Conte; L Maggi; S Fiorelli; M Mercieri; C Balestra; R A De Blasi
Journal:  Eur J Appl Physiol       Date:  2018-10-22       Impact factor: 3.078

Review 6.  Symptoms of central nervous system oxygen toxicity during 100% oxygen breathing at normobaric pressure with increasing inspired levels of carbon dioxide: a case report.

Authors:  Mirit Eynan; Yehuda Arieli; Boris Taran; Yoav Yanir
Journal:  Diving Hyperb Med       Date:  2020-03-31       Impact factor: 0.887

7.  Adult attention-deficit/hyperactivity disorder prevalence among commercial divers in South Africa.

Authors:  Charles H Van Wijk; W A Jack Meintjes
Journal:  Diving Hyperb Med       Date:  2020-06-30       Impact factor: 0.887

Review 8.  Oxygen Toxicity and Special Operations Forces Diving: Hidden and Dangerous.

Authors:  Thijs T Wingelaar; Pieter-Jan A M van Ooij; Rob A van Hulst
Journal:  Front Psychol       Date:  2017-07-25

9.  Necrostatin-1 prolongs latency to convulsion in mice exposed to high oxygen partial pressure.

Authors:  Zhen-Biao Guan; Yan-Yan Zhou; Yi Cen; Han-De Feng; Wen-Wu Liu; Hong-Jie Yi; Hui Chen
Journal:  Diving Hyperb Med       Date:  2021-06-30       Impact factor: 1.228

10.  Oxygen toxicity seizures during United States Navy Treatment Table 6: An acceptable risk in monoplace chambers?

Authors:  Samantha Bonnington; Neil Banham; Kevin Foley; Ian Gawthrope
Journal:  Diving Hyperb Med       Date:  2021-06-30       Impact factor: 1.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.